{"product_id":"slgl-ansoff-analysis","title":"(SLGL) Sol-Gel Technologies Ltd. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUnlock the Full Ansoff Matrix for Deeper Strategic Insight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Sol-Gel Technologies Ltd. Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification, showing what initiatives and risks to prioritize; the page includes a real preview\/sample of the analysis so you can judge style and substance before buying. Purchase the full version to receive the complete, ready-to-use company-specific Ansoff Matrix report.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTwyneo acne commercialization through Perrigo\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwyneo is a once-daily, non-antibiotic topical cream for acne vulgaris, and Sol-Gel Technologies Ltd. has already completed Phase III development, so the market penetration play is deeper use in an existing market, not a new launch category. The Perrigo partnership is the main commercialization route, which should help convert clinical progress into shelf space, prescriptions, and repeat use. In Ansoff terms, this is classic share building: same product, same acne market, with the goal of taking more of the existing demand.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEpsolay rosacea commercialization through Perrigo\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEpsolay, Sol-Gel Technologies Ltd.'s once-daily 5% benzoyl peroxide cream for papulopustular rosacea, is already in the prescription dermatology channel, so Perrigo can push deeper adoption instead of building a new market. With Phase III completed and U.S. rosacea care serving millions of patients, the play is to win share from existing prescribers and switch users from older topicals. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOnce-daily non-antibiotic topical positioning\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. uses Twyneo and Epsolay as once-daily topical options, and Twyneo’s non-antibiotic profile is a clear edge in acne care. That matters in a U.S. acne market where treatment choice is often driven by tolerability and resistance concerns, supporting switching and retention in dermatology clinics. With 2 commercial branded topicals, Sol-Gel can compete harder in its current market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTopical dermatology generics in existing channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSol-Gel Technologies can use topical dermatology generics to widen share in the same prescriber and pharmacy channels it already serves with branded products. This is classic market penetration: more volume through current infrastructure, lower launch friction, and better access for price-sensitive patients and payers. Generic lines can support repeat use and broaden reach without opening a new market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSame channels, more volume\u003c\/li\u003e\n\u003cli\u003eLower-cost access helps uptake\u003c\/li\u003e\n\u003cli\u003eBrands and generics can coexist\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMicroencapsulation-led differentiation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSol-Gel’s proprietary microencapsulation platform is a direct market-penetration lever: it can lift skin delivery, stability, and tolerability in existing acne and rosacea products. Acne affects about 50 million Americans each year, and rosacea about 16 million, so even small gains in performance can support stronger uptake. The same core tech also helps the brand stand out without changing the addressable market.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBetter drug delivery\u003c\/li\u003e\n\u003cli\u003eStronger product differentiation\u003c\/li\u003e\n\u003cli\u003eHigher uptake in core markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSol-Gel Deepens Dermatology Share With Twyneo and Epsolay\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. is using Twyneo and Epsolay to deepen share in acne and rosacea, so this is market penetration, not a new market bet. Perrigo gives it an existing U.S. dermatology route, which lowers launch friction and supports repeat prescribing. Acne affects about 50 million Americans a year and rosacea about 16 million, so small share gains can matter.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eDriver\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTwyneo\u003c\/td\u003e\n\u003ctd\u003eOnce-daily, non-antibiotic acne cream\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEpsolay\u003c\/td\u003e\n\u003ctd\u003eOnce-daily 5% benzoyl peroxide rosacea cream\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcne market\u003c\/td\u003e\n\u003ctd\u003eAbout 50 million Americans yearly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRosacea market\u003c\/td\u003e\n\u003ctd\u003eAbout 16 million Americans\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eAnalyzes Sol-Gel Technologies Ltd.’s growth strategy through the four core directions of the Ansoff Matrix\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick Sol-Gel Technologies Ltd. Ansoff Matrix view to simplify growth planning and resolve strategy gaps fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise bibliography of primary, regulatory, and industry sources to validate Sol-Gel Technologies’ Ansoff Matrix growth assumptions and speed due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePerrigo-led geographic expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. uses Perrigo to move Twyneo and Epsolay beyond Israel through partner-led commercialization, so the same approved formulations can enter new markets without changing the core product.\u003c\/p\u003e\n\u003cp\u003eThat makes this a clean market-development play: 2 FDA-approved products, 1 commercial partner, and wider reach in the U.S. and other territories with lower launch spend than a solo rollout.\u003c\/p\u003e\n\u003cp\u003ePerrigo’s scale helps Sol-Gel turn its dermatology assets into geographic growth while keeping manufacturing and formulation unchanged.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFrom Israel-centered operations to wider regions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. keeps development and commercialization rooted in Israel, and that base supports moving existing dermatology products into new markets through regulatory filings, local partnerships, and sales rollout. This is market development, not new-product creation: the same products, wider geography. The move fits Ansoff because the growth lever is regional access, not pipeline expansion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExisting acne therapy into broader dermatology markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTwyneo, Sol-Gel Technologies Ltd.’s once-daily, non-antibiotic acne treatment, fits market development because acne vulgaris affects up to 50 million Americans each year and remains one of dermatology’s largest topical categories. The same approved product can be pushed into broader prescription dermatology use and new geographies without changing the core asset. That expands reach while keeping the label and dosing intact.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eExisting rosacea therapy into additional territories\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEpsolay targets papulopustular rosacea, a large existing dermatology niche tied to the 16 million Americans with rosacea. Selling the same product into more countries is classic market development: no reformulation, just a wider launch of the same value proposition. That can scale revenue faster than R\u0026amp;D because the core clinical story is already set.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew territories, same product\u003c\/li\u003e\n\u003cli\u003eLow-change, high-reach move\u003c\/li\u003e\n\u003cli\u003eUses existing rosacea demand\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeneric topical dermatology expansion by geography\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. can extend its generic topical dermatology line into new geographies through local partners, using the same product concepts across markets. This fits products with simpler registration and local manufacturing paths, and it can add revenue without building a full new brand from scratch. The move also supports the company’s 2 branded products, Epsolay and Twyneo, by broadening its dermatology reach.\u003c\/p\u003e\n\u003cp\u003eDistilled: \n\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses existing topical IP across markets\u003c\/li\u003e\n\u003cli\u003eFits partner-led cross-border entry\u003c\/li\u003e\n\u003cli\u003eAdds reach beyond branded assets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSol-Gel's Two Dermatology Assets Target Massive U.S. Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. is a market-development case: Twyneo and Epsolay can grow in new geographies through Perrigo-led rollout, without changing the core products. That matters in large U.S. dermatology pools—up to 50 million acne patients and 16 million rosacea patients—so the same assets can scale across markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved products\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore demand pools\u003c\/td\u003e\n\u003ctd\u003e50M acne; 16M rosacea\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eSol-Gel Technologies Ltd. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report you'll get; buy now to unlock the complete, editable Ansoff Matrix with strategic recommendations tailored to Sol-Gel Technologies Ltd.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSGT-210 for palmoplantar keratoderma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSGT-210 is Sol-Gel Technologies Ltd.'s Phase I candidate for palmoplantar keratoderma, so this is a clear product development move: a new dermatology asset added to an existing clinical and commercial base. It broadens the pipeline beyond current skin-disease programs and targets a niche rare-disease market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTopical erlotinib for psoriasis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd.'s topical erlotinib work for psoriasis is a product development move: it extends the dermatology pipeline beyond acne and rosacea into a new indication. That matters because the company is broadening one topical platform to serve more skin diseases, not just adding a new market. In 2025\/2026, this kind of line extension can lift pipeline value without rebuilding the delivery system from scratch.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTopical tapinarof for psoriasis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTopical tapinarof for psoriasis is a clear product development move for Sol-Gel Technologies Ltd., adding a new non-steroidal topical option to its dermatology line. Psoriasis affects about 125 million people worldwide, so even one more effective skin treatment can expand the addressable market. This broadens Sol-Gel’s portfolio beyond its current assets and supports a deeper dermatology focus.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eTopical roflumilast for psoriasis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTopical roflumilast for psoriasis is a product-development move for Sol-Gel Technologies Ltd., adding a new dermatology candidate to a portfolio that already includes topical products. Psoriasis affects about 125 million people worldwide, so even a small share can support future sales and widen commercialization options.\u003c\/p\u003e\n\u003cp\u003eFor Sol-Gel Technologies Ltd., this deepens the pipeline and reduces dependence on one asset; the company reported $31.7 million in cash and cash equivalents at 2025 year-end, which helps fund development. It is a clear move to create a second or third skin-care revenue path.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew psoriasis indication\u003c\/li\u003e\n\u003cli\u003ePipeline depth grows\u003c\/li\u003e\n\u003cli\u003eMore launch optionality\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eGeneric topical dermatology pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSol-Gel Technologies is using its dermatology formulation know-how to build generic topical drugs, a clear product development move in Ansoff. With 2 FDA-approved U.S. products already in its portfolio, adding generics can broaden the pipeline without leaving skin care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUses existing topical formulation expertise\u003c\/li\u003e\n\u003cli\u003eAdds more launchable dermatology lines\u003c\/li\u003e\n\u003cli\u003eKeeps focus on skin-care markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSol-Gel Expands Dermatology Pipeline With $31.7M Cash\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. is using product development by extending its dermatology platform into new skin indications and topical assets, including SGT-210 for palmoplantar keratoderma and topical erlotinib, tapinarof, and roflumilast for psoriasis.\u003c\/p\u003e\n\u003cp\u003eThis deepens the pipeline without leaving skin care, and Sol-Gel Technologies Ltd. had $31.7 million in cash and cash equivalents at 2025 year-end to support development.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eItem\u003c\/th\u003e\n\u003cth\u003e2025\/2026 data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash and cash equivalents\u003c\/td\u003e\n\u003ctd\u003e$31.7 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKey move\u003c\/td\u003e\n\u003ctd\u003eNew dermatology indications\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePsoriasis pipeline expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. is pushing beyond acne and rosacea into psoriasis, which fits Ansoff diversification because it adds new products for a new disease area. Psoriasis affects about 125 million people worldwide, so the addressable market is large. Erlotinib, tapinarof, and roflumilast strengthen this dermatology shift and widen Sol-Gel’s scope.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePalmoplantar keratoderma entry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSGT-210 for palmoplantar keratoderma moves Sol-Gel Technologies Ltd. into a new indication beyond its core acne and rosacea products, so this is diversification at the indication level. In 2025, the asset remained a specialty-dermatology bet with no commercial sales yet, but it broadens the pipeline into an ultra-niche rare skin disorder. The move adds new-market exposure and could reduce reliance on the company’s current product base.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBranded and generic dermatology mix\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. is not tied to one product lane: it pairs branded dermatology assets like TWYNEO and EPSOLAY with generic topical medicines. That gives it two commercial tracks in the same therapeutic area, so it can spread risk across premium and volume-driven sales. In its latest filings, the company reported no broad product concentration, but it still depends on a small dermatology portfolio, so this mix is practical diversification, not full insulation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eMicroencapsulation platform across multiple indications\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. uses one microencapsulation platform to support multiple skin-applied medicines, so the same core tech can move across more than one indication. That widens the product scope beyond a single launch and lowers reliance on one disease area. It is classic diversification through platform reuse.\u003c\/p\u003e\n\u003cp\u003eIt also fits a better risk mix: one platform, more shots at market entry, and less exposure to any one trial or label outcome.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroader indication coverage\u003c\/li\u003e\n\u003cli\u003eLess single-product risk\u003c\/li\u003e\n\u003cli\u003eReuse cuts R\u0026amp;D waste\u003c\/li\u003e\n\u003cli\u003eMore launch options\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartner-backed dermatology portfolio buildout\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePerrigo's backing gives Sol-Gel Technologies Ltd. a wider commercialization lane than its 2 lead dermatology products alone. It can pair internal R\u0026amp;D with Perrigo's sales and distribution reach, so the company can add more skin-care assets without building a full commercial stack from scratch.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBroader product reach\u003c\/li\u003e\n\u003cli\u003eControlled market expansion\u003c\/li\u003e\n\u003cli\u003eR\u0026amp;D plus partner sales power\u003c\/li\u003e\n\u003cli\u003eLess reliance on 2 products\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSol-Gel Broadens Beyond Acne With Psoriasis and Rare Skin Disorder Bets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSol-Gel Technologies Ltd. uses diversification to move beyond acne and rosacea into psoriasis and rare skin disorders like SGT-210 for palmoplantar keratoderma. With about 125 million people affected by psoriasis worldwide and no commercial sales yet from these new bets in 2025, the strategy widens its dermatology reach while reducing reliance on TWYNEO and EPSOLAY.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePsoriasis\u003c\/td\u003e\n\u003ctd\u003e125M global cases\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLead products\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNew bets\u003c\/td\u003e\n\u003ctd\u003eNo sales yet\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234989711625,"sku":"slgl-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/slgl-ansoff-matrix.webp?v=1785731790","url":"https:\/\/dcfanalyst.com\/products\/slgl-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}